Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor
2025-SR-691
Phase 2 small_molecule active
Quick answer
Radiotherapy Combined with Anlotinib and a Microtubule Inhibitor for HER2-Negative Breast Cancer is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- HER2-Negative Breast Cancer
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active